This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Triyatni, M.
Right arrow Articles by Burrell, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Triyatni, M.
Right arrow Articles by Burrell, C. J.

 Previous Article  |  Next Article 

J. Virol., Jan 1998, 84-94, Vol 72, No. 1
Copyright © 1998, American Society for Microbiology

Protective efficacy of DNA vaccines against duck hepatitis B virus infection

M Triyatni, AR Jilbert, M Qiao, DS Miller and CJ Burrell
Department of Microbiology and Immunology, University of Adelaide, South Australia. mtryatni@microb.adelaide.edu.au

The efficacy of DNA vaccines encoding the duck hepatitis B virus (DHBV) pre-S/S and S proteins were tested in Pekin ducks. Plasmid pcDNA I/Amp DNA containing the DHBV pre-S/S or S genes was injected intramuscularly three times, at 3-week intervals. All pre-S/S and S-vaccinated ducks developed total anti-DHBs and specific anti-S antibodies with similar titers reaching 1/10,000 to 1/50,000 and 1/2,500 to 1/4,000, respectively, after the third vaccination. However, following virus challenge, significant differences in the rate of virus removal from the bloodstream and the presence of virus replication in the liver were found between the groups. In three of four S-vaccinated ducks, 90% of the inoculum was removed between <5 and 15 min postchallenge (p.c.) and no virus replication was detected in the liver at 4 days p.c. In contrast, in all four pre-S/S-vaccinated ducks, 90% of the inoculum was removed between 60 and 90 min p.c. and DHBsAg was detected in 10 to 40% of hepatocytes. Anti-S serum abolished virus infectivity when preincubated with DHBV before inoculation into 1-day-old ducklings and primary duck hepatocyte cultures, while anti-pre-S/S serum showed very limited capacity to neutralize virus infectivity in these two systems. Thus, although both DNA vaccines induced high titers of anti-DHBs antibodies, anti-S antibodies induced by the S-DNA construct were highly effective in neutralizing virus infectivity while similar levels of anti-S induced by the pre-S/S-DNA construct conferred only very limited protection. This phenomenon requires further clarification, particularly in light of the development of newer HBV vaccines containing pre-S proteins and a possible discrepancy between anti-HBs titers and protective efficacy.


This article has been cited by other articles:

  • Thermet, A., Buronfosse, T., Werle-Lapostolle, B., Chevallier, M., Pradat, P., Trepo, C., Zoulim, F., Cova, L. (2008). DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection. J. Gen. Virol. 89: 1192-1201 [Abstract] [Full Text]  
  • Wang, J., Gujar, S. A., Cova, L., Michalak, T. I. (2007). Bicistronic Woodchuck Hepatitis Virus Core and Gamma Interferon DNA Vaccine Can Protect from Hepatitis but Does Not Elicit Sterilizing Antiviral Immunity. J. Virol. 81: 903-916 [Abstract] [Full Text]  
  • Gares, S. L., Fischer, K. P., Congly, S. E., Lacoste, S., Addison, W. R., Tyrrell, D. L., Gutfreund, K. S. (2006). Immunotargeting with CD154 (CD40 Ligand) Enhances DNA Vaccine Responses in Ducks. CVI 13: 958-965 [Abstract] [Full Text]  
  • Thermet, A., Robaczewska, M., Rollier, C., Hantz, O., Trepo, C., Deleage, G., Cova, L. (2004). Identification of Antigenic Regions of Duck Hepatitis B Virus Core Protein with Antibodies Elicited by DNA Immunization and Chronic Infection. J. Virol. 78: 1945-1953 [Abstract] [Full Text]  
  • Foster, W. K., Miller, D. S., Marion, P. L., Colonno, R. J., Kotlarski, I., Jilbert, A. R. (2003). Entecavir Therapy Combined with DNA Vaccination for Persistent Duck Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 47: 2624-2635 [Abstract] [Full Text]  
  • Karayiannis, P. (2003). Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother 51: 761-785 [Abstract] [Full Text]  
  • Siegel, F., Lu, M., Roggendorf, M. (2001). Coadministration of Gamma Interferon with DNA Vaccine Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen Enhances the Specific Immune Response and Protects against WHV Infection. J. Virol. 75: 5036-5042 [Abstract] [Full Text]  
  • Rollier, C., Charollois, C., Jamard, C., Trepo, C., Cova, L. (2000). Maternally Transferred Antibodies from DNA-Immunized Avians Protect Offspring against Hepadnavirus Infection. J. Virol. 74: 4908-4911 [Abstract] [Full Text]  
  • Lu, M., Hilken, G., Kruppenbacher, J., Kemper, T., Schirmbeck, R., Reimann, J., Roggendorf, M. (1999). Immunization of Woodchucks with Plasmids Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen and Surface Antigen Suppresses WHV Infection. J. Virol. 73: 281-289 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»